Sign up for free.
Sirtex is a global healthcare leader dedicated to developing and marketing innovative, minimally invasive cancer treatments. The company is committed to improving the quality and duration of life for cancer patients through advanced interventional oncology solutions.
Sirtex's main product is SIR-Spheres® Y-90 Resin Microspheres, a targeted radiation therapy for the treatment of liver cancer. This technology is used in over 50 countries and has already positively impacted the lives of over 150,000 patients worldwide. SIR-Spheres® Y-90 Resin Microspheres are indicated for the treatment of unresectable hepatocellular carcinoma (HCC), unresectable metastatic liver tumors from primary colorectal cancer (mCRC) in patients who are refractory or intolerant to chemotherapy, unresectable intrahepatic cholangiocarcinoma (iCCA), and liver metastases from neuroendocrine tumors (mNET).
In addition to SIR-Spheres®, Sirtex offers the LAVA® Liquid Embolic System, the first and only liquid embolic agent approved for the treatment of peripheral vascular hemorrhages.
Sirtex works closely with physicians to provide innovative products that improve treatment outcomes and simplify treatments. The company values professionalism, a collaborative work culture, entrepreneurship, and continuous innovation and improvement.
The corporate culture of Sirtex is based on the values of Compassion, Advancement, Reputation, and Empowerment (CARE). Sirtex is committed to diversity, equity, and inclusion, creating an open and inclusive environment where all employees can thrive.
Sirtex invests in research and innovation to further advance the treatment of liver cancer. The company supports research projects and studies to improve the understanding of liver cancer and the effectiveness of its products.
